Saving of stem cell from births increases significantly for NextCell´s biobank Cellaviva
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark.Cellaviva offers new parents the opportunity to save their child´s stem cells for therapeutic treatment of diseases the family has suffered from, or risk being affected of in the future. Stem cells are collected from the umbilical cord after the umbilical cord has been cut